Arrowhead Pharmaceuticals' Plozasiran Could Drive Stock Re-rating
Arrowhead Pharmaceuticals (NASDAQ:ARWR) achieved a key milestone in Germany with the availability of REDEMPLO for Familial Chylomicronemia Syndrome, following European Commission approval. The drug can now be prescribed based on clinical symptoms or genetic tests without requiring full genetic confirmation every three months. In its fiscal Q3 2026 report released August 4, Arrowhead saw a significant revenue increase of $75.3 million driven by collaboration income and rising U.S. prescriptions for REDEMPLO. However, the company reported an expanded net loss due to R&D costs and commercial launch expenses. Analysts remain optimistic about plozasiran's potential after H.C. Wainwright raised its price target from $115 to $120 while maintaining a Buy rating. Positive Phase III trial data supports long-term therapeutic value, but concerns persist around unprofitability and uncertain cash flow.
Tickers: $ARWR
Topics: Arrowhead Pharmaceuticals financial performance market re-rating Plozasiran REDEMPLO